The “extreme phenotype approach” applied to male breast cancer allows the identification of rare variants of ATR as potential breast cancer susceptibility alleles
暂无分享,去创建一个
J. Rivière | R. Boidot | L. Faivre | Y. Bignon | P. Jonveaux | F. Ghiringhelli | Y. Duffourd | C. Thauvin | J. Albuisson | P. Callier | I. Coupier | M. Collonge-Rame | A. Baurand | G. Bertolone | P. Kuentz | C. Populaire | S. Nambot | M. Chevarin | Monique Mozelle-Nivoix | Z. Selmani | Diana Alcantara | C. Sawka | François Cornélis | Christophe Cordier | Marc O'Driscoll | François Cornelis
[1] A. Spurdle,et al. SPiP: Splicing Prediction Pipeline, a machine learning tool for massive detection of exonic and intronic variant effects on mRNA splicing , 2022, Human mutation.
[2] Marc S. Williams,et al. Penetrance of Breast Cancer Susceptibility Genes From the eMERGE III Network , 2021, JNCI cancer spectrum.
[3] S. Steinberg,et al. Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. , 2021, Cancer cell.
[4] A. Melcher,et al. ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment , 2019, Clinical Cancer Research.
[5] B. Bonanni,et al. Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy , 2019, International journal of cancer.
[6] M. Bihoreau,et al. Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing , 2018, International journal of cancer.
[7] Sitao Wu,et al. Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing , 2019, JAMA Oncology.
[8] M. Hung,et al. Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. , 2018, American journal of cancer research.
[9] M. Tainsky,et al. Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability , 2017, PloS one.
[10] A. Lerário,et al. A new POT1 germline mutation—expanding the spectrum of POT1-associated cancers , 2017, Familial Cancer.
[11] N. Rhind,et al. The Intra-S Checkpoint Responses to DNA Damage , 2017, Genes.
[12] F. Couch,et al. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results , 2016, Breast Cancer Research and Treatment.
[13] Alexander Hoischen,et al. New insights into the generation and role of de novo mutations in health and disease , 2016, Genome Biology.
[14] R. Scott,et al. Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] P. Broderick,et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer , 2016, Nature Communications.
[16] N. Seyfried,et al. ATRIP Deacetylation by SIRT2 Drives ATR Checkpoint Activation by Promoting Binding to RPA-ssDNA. , 2016, Cell reports.
[17] S. Fox,et al. The cancer genetics and pathology of male breast cancer , 2016, Histopathology.
[18] James Y. Zou. Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.
[19] J. Benítez,et al. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study , 2015, Familial Cancer.
[20] Abdelghani Mazouzi,et al. DNA replication stress: causes, resolution and disease. , 2014, Experimental cell research.
[21] Nazneen Rahman,et al. Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.
[22] Cailyn H. Spurrell. Identifying New Genes for Inherited Breast Cancer by Exome Sequencing , 2014 .
[23] J. Shendure,et al. A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.
[24] M. King,et al. Germline Mutations of Inhibins in Early-Onset Ovarian Epithelial Tumors , 2013, Human mutation.
[25] P. Ang,et al. Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.
[26] K. Boycott,et al. Rare-disease genetics in the era of next-generation sequencing: discovery to translation , 2013, Nature Reviews Genetics.
[27] D. Goldstein,et al. Genic Intolerance to Functional Variation and the Interpretation of Personal Genomes , 2013, PLoS genetics.
[28] J. Ferlay,et al. An international comparison of male and female breast cancer incidence rates , 2013, International journal of cancer.
[29] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[30] D. Eccles,et al. Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas , 2013, Nature Genetics.
[31] A. Fischer,et al. Primary Microcephaly, Impaired DNA Replication, and Genomic Instability Caused by Compound Heterozygous ATR Mutations , 2013, Human mutation.
[32] P. Jeggo,et al. Identification of the First ATRIP–Deficient Patient and Novel Mutations in ATR Define a Clinical Spectrum for ATR–ATRIP Seckel Syndrome , 2012, PLoS genetics.
[33] R. Tothill,et al. Exome Sequencing Identifies Rare Deleterious Mutations in DNA Repair Genes FANCC and BLM as Potential Breast Cancer Susceptibility Alleles , 2012, PLoS genetics.
[34] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[35] G. McArthur,et al. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells , 2012, Oncogene.
[36] Aung Ko Win,et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Yuhki Yanase,et al. Germline mutation in ATR in autosomal- dominant oropharyngeal cancer syndrome. , 2012, American journal of human genetics.
[38] O. Fernandez-Capetillo,et al. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. , 2012, The Journal of clinical investigation.
[39] M. Barbacid,et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors , 2011, Nature Structural &Molecular Biology.
[40] A. Knudson,et al. A continuum model for tumour suppression , 2011, Nature.
[41] P. Oefner,et al. Rare variants in the ATM gene and risk of breast cancer , 2011, Breast Cancer Research.
[42] J. Benítez,et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma , 2011, Nature Genetics.
[43] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[44] B. Nabet,et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. , 2010, Cancer research.
[45] S. Kaufmann,et al. Prospects for the Use of ATR Inhibitors to Treat Cancer , 2010, Pharmaceuticals.
[46] J. Bergh,et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[48] J. Potter,et al. Lynch Syndrome–Associated Breast Cancers: Clinicopathologic Characteristics of a Case Series from the Colon Cancer Family Registry , 2010, Clinical Cancer Research.
[49] T. Halazonetis,et al. Emerging common themes in regulation of PIKKs and PI3Ks , 2009, The EMBO journal.
[50] F. Mulero,et al. A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging , 2009, Nature Genetics.
[51] K. Ko,et al. Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response , 2009, Nucleic acids research.
[52] C. Béroud,et al. Human Splicing Finder: an online bioinformatics tool to predict splicing signals , 2009, Nucleic acids research.
[53] J. Kobayashi,et al. Inactivation of the Nijmegen breakage syndrome gene leads to excess centrosome duplication via the ATR/BRCA1 pathway. , 2009, Cancer research.
[54] S. Shanley,et al. The G67E mutation in hMLH1 is associated with an unusual presentation of Lynch syndrome , 2009, British Journal of Cancer.
[55] J. Foekens,et al. CHEK2 1100delC and male breast cancer in the Netherlands , 2009, Breast Cancer Research and Treatment.
[56] S. Elledge,et al. How ATR turns on: TopBP1 goes on ATRIP with ATR. , 2008, Genes & development.
[57] A. van den Berg,et al. ATR alterations in Hodgkin's lymphoma. , 2008, Oncology reports.
[58] O. Fernandez-Capetillo,et al. ATR signaling can drive cells into senescence in the absence of DNA breaks. , 2008, Genes & development.
[59] Giovanni Parmigiani,et al. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. , 2007, Journal of the National Cancer Institute.
[60] S. Thibodeau,et al. Mutations in the ataxia telangiectasia and rad3‐related–checkpoint kinase 1 DNA damage response axis in colon cancers , 2007, Genes, chromosomes & cancer.
[61] P. Jeggo,et al. Cellular and clinical impact of haploinsufficiency for genes involved in ATR signaling. , 2007, American journal of human genetics.
[62] D. Labuda,et al. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families , 2006, BMC Cancer.
[63] Nazneen Rahman,et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles , 2006, Nature Genetics.
[64] Penny A. Jeggo,et al. The role of double-strand break repair — insights from human genetics , 2006, Nature Reviews Genetics.
[65] S. Boulton,et al. Distinct modes of ATR activation after replication stress and DNA double‐strand breaks in Caenorhabditis elegans , 2005, The EMBO journal.
[66] J. Chien,et al. Heterozygous ATR mutations in mismatch repair-deficient cancer cells have functional significance. , 2005, Cancer research.
[67] S. Batzoglou,et al. Distribution and intensity of constraint in mammalian genomic sequence. , 2005, Genome research.
[68] Lesley McGuffog,et al. Cancer risks and mortality in heterozygous ATM mutation carriers. , 2005, Journal of the National Cancer Institute.
[69] L. Maquat,et al. Mechanistic links between nonsense-mediated mRNA decay and pre-mRNA splicing in mammalian cells. , 2005, Current opinion in cell biology.
[70] Robert Winqvist,et al. Mutation analysis of the ATR gene in breast and ovarian cancer families , 2005, Breast Cancer Research.
[71] M. Pacek,et al. Functional uncoupling of MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint. , 2005, Genes & development.
[72] K. Aozasa,et al. Alterations of DNA damage-response genes ATM and ATR in pyothorax-associated lymphoma , 2005, Laboratory Investigation.
[73] W. Cliby,et al. Ataxia Telangiectasia Mutated (ATM) and ATM and Rad3-related Protein Exhibit Selective Target Specificities in Response to Different Forms of DNA Damage* , 2005, Journal of Biological Chemistry.
[74] Helen Swede,et al. Epidemiology of male breast cancer. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[75] J. Boyd,et al. Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome , 2004, Breast Cancer Research and Treatment.
[76] Judith A. Goodship,et al. A splicing mutation affecting expression of ataxia–telangiectasia and Rad3–related protein (ATR) results in Seckel syndrome , 2003, Nature Genetics.
[77] D. Baltimore,et al. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. , 2003, Genes & development.
[78] R. Mariani-Costantini,et al. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. , 2003, Cancer research.
[79] T. Glover,et al. ATR Regulates Fragile Site Stability , 2002, Cell.
[80] Nazneen Rahman,et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.
[81] The Polish Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002 .
[82] Jun Qin,et al. ATR and ATRIP: Partners in Checkpoint Signaling , 2001, Science.
[83] S. Schreiber,et al. ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[84] O. Olopade,et al. Male breast cancer in Cowden syndrome patients with germlinePTEN mutations , 2001, Journal of medical genetics.
[85] O. Olopade,et al. Male breast cancer in Cowden syndrome patients with germline PTEN mutations , 2001 .
[86] A. Carr,et al. Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice , 2000, Current Biology.
[87] D. Baltimore,et al. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. , 2000, Genes & development.
[88] B. Ponder,et al. High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. , 1999, Cancer research.
[89] Jing Li,et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.
[90] B. Ponder,et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. , 1997, American journal of human genetics.